Aktienanalyse zu Pacira Biosciences Inc (PCRX)PCRXPacira Biosciences Inc

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pacira Biosciences Inc (PCRX) is currently a hold. The stock is trading at $36.42, very close to the acquisition price of $36.50 per share offered by Viatris, which represents a 44.8% premium over recent prices. The RSI is at 90.571, indicating overbought conditions, and while the forward P/E ratio is a low 6.25, the recent insider selling has increased by 636.27%, which raises concerns about future performance. Given these factors, it is prudent to hold until the acquisition is finalized.

16 analysts cover PCRX: 10 rate it Buy, 5 Hold and 1 Sell. The average price target is 30.33.